nodes	percent_of_prediction	percent_of_DWPC	metapath
Reboxetine—HTR2C—Sorafenib—liver cancer	0.266	0.435	CbGbCtD
Reboxetine—ABCB1—Sorafenib—liver cancer	0.0846	0.138	CbGbCtD
Reboxetine—CYP2D6—Sorafenib—liver cancer	0.0797	0.13	CbGbCtD
Reboxetine—ABCB1—Doxorubicin—liver cancer	0.0513	0.084	CbGbCtD
Reboxetine—CYP3A4—Sorafenib—liver cancer	0.0507	0.0829	CbGbCtD
Reboxetine—CYP2D6—Doxorubicin—liver cancer	0.0483	0.0791	CbGbCtD
Reboxetine—CYP3A4—Doxorubicin—liver cancer	0.0307	0.0503	CbGbCtD
Reboxetine—Infestation NOS—Sorafenib—liver cancer	0.00176	0.00551	CcSEcCtD
Reboxetine—Infestation—Sorafenib—liver cancer	0.00176	0.00551	CcSEcCtD
Reboxetine—Seborrhoeic dermatitis—Epirubicin—liver cancer	0.0017	0.00534	CcSEcCtD
Reboxetine—Hyperventilation—Epirubicin—liver cancer	0.00169	0.00529	CcSEcCtD
Reboxetine—Epistaxis—Sorafenib—liver cancer	0.00166	0.0052	CcSEcCtD
Reboxetine—Hyperlipidaemia—Epirubicin—liver cancer	0.00161	0.00505	CcSEcCtD
Reboxetine—Seborrhoeic dermatitis—Doxorubicin—liver cancer	0.00157	0.00494	CcSEcCtD
Reboxetine—Hyperventilation—Doxorubicin—liver cancer	0.00156	0.0049	CcSEcCtD
Reboxetine—Urinary tract disorder—Sorafenib—liver cancer	0.00156	0.00489	CcSEcCtD
Reboxetine—Albuminuria—Epirubicin—liver cancer	0.00155	0.00488	CcSEcCtD
Reboxetine—Connective tissue disorder—Sorafenib—liver cancer	0.00155	0.00486	CcSEcCtD
Reboxetine—Urethral disorder—Sorafenib—liver cancer	0.00154	0.00485	CcSEcCtD
Reboxetine—Hyperlipidaemia—Doxorubicin—liver cancer	0.00149	0.00467	CcSEcCtD
Reboxetine—Tinnitus—Sorafenib—liver cancer	0.00147	0.00461	CcSEcCtD
Reboxetine—Cardiac disorder—Sorafenib—liver cancer	0.00146	0.00459	CcSEcCtD
Reboxetine—Albuminuria—Doxorubicin—liver cancer	0.00144	0.00451	CcSEcCtD
Reboxetine—Angiopathy—Sorafenib—liver cancer	0.00143	0.00449	CcSEcCtD
Reboxetine—Immune system disorder—Sorafenib—liver cancer	0.00142	0.00447	CcSEcCtD
Reboxetine—Mediastinal disorder—Sorafenib—liver cancer	0.00142	0.00446	CcSEcCtD
Reboxetine—Mental disorder—Sorafenib—liver cancer	0.00138	0.00433	CcSEcCtD
Reboxetine—Malnutrition—Sorafenib—liver cancer	0.00137	0.00431	CcSEcCtD
Reboxetine—Dysgeusia—Sorafenib—liver cancer	0.00134	0.00422	CcSEcCtD
Reboxetine—Amenorrhoea—Epirubicin—liver cancer	0.00132	0.00414	CcSEcCtD
Reboxetine—Ventricular extrasystoles—Epirubicin—liver cancer	0.00128	0.00403	CcSEcCtD
Reboxetine—Viral infection—Epirubicin—liver cancer	0.00128	0.00403	CcSEcCtD
Reboxetine—Anaemia—Sorafenib—liver cancer	0.00127	0.00398	CcSEcCtD
Reboxetine—Thinking abnormal—Epirubicin—liver cancer	0.00127	0.00398	CcSEcCtD
Reboxetine—Glossitis—Epirubicin—liver cancer	0.00126	0.00395	CcSEcCtD
Reboxetine—Hyperuricaemia—Epirubicin—liver cancer	0.00125	0.00393	CcSEcCtD
Reboxetine—Syncope—Sorafenib—liver cancer	0.00123	0.00386	CcSEcCtD
Reboxetine—Leukopenia—Sorafenib—liver cancer	0.00123	0.00386	CcSEcCtD
Reboxetine—Amenorrhoea—Doxorubicin—liver cancer	0.00122	0.00383	CcSEcCtD
Reboxetine—Loss of consciousness—Sorafenib—liver cancer	0.00121	0.00379	CcSEcCtD
Reboxetine—Viral infection—Doxorubicin—liver cancer	0.00119	0.00373	CcSEcCtD
Reboxetine—Ventricular extrasystoles—Doxorubicin—liver cancer	0.00119	0.00373	CcSEcCtD
Reboxetine—Hypertension—Sorafenib—liver cancer	0.00118	0.00372	CcSEcCtD
Reboxetine—Coordination abnormal—Epirubicin—liver cancer	0.00118	0.00371	CcSEcCtD
Reboxetine—Blood uric acid increased—Epirubicin—liver cancer	0.00118	0.00371	CcSEcCtD
Reboxetine—Neck pain—Epirubicin—liver cancer	0.00117	0.00369	CcSEcCtD
Reboxetine—Thinking abnormal—Doxorubicin—liver cancer	0.00117	0.00368	CcSEcCtD
Reboxetine—Glossitis—Doxorubicin—liver cancer	0.00116	0.00366	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00116	0.00364	CcSEcCtD
Reboxetine—Hyperuricaemia—Doxorubicin—liver cancer	0.00116	0.00363	CcSEcCtD
Reboxetine—Dry mouth—Sorafenib—liver cancer	0.00114	0.00359	CcSEcCtD
Reboxetine—Salivary hypersecretion—Epirubicin—liver cancer	0.00113	0.00354	CcSEcCtD
Reboxetine—Infection—Sorafenib—liver cancer	0.00111	0.00349	CcSEcCtD
Reboxetine—Shock—Sorafenib—liver cancer	0.0011	0.00346	CcSEcCtD
Reboxetine—Nervous system disorder—Sorafenib—liver cancer	0.0011	0.00345	CcSEcCtD
Reboxetine—Blood uric acid increased—Doxorubicin—liver cancer	0.00109	0.00343	CcSEcCtD
Reboxetine—Coordination abnormal—Doxorubicin—liver cancer	0.00109	0.00343	CcSEcCtD
Reboxetine—Skin disorder—Sorafenib—liver cancer	0.00109	0.00341	CcSEcCtD
Reboxetine—Neck pain—Doxorubicin—liver cancer	0.00109	0.00341	CcSEcCtD
Reboxetine—Anorexia—Sorafenib—liver cancer	0.00107	0.00335	CcSEcCtD
Reboxetine—Salivary hypersecretion—Doxorubicin—liver cancer	0.00104	0.00327	CcSEcCtD
Reboxetine—Mental disability—Epirubicin—liver cancer	0.00101	0.00316	CcSEcCtD
Reboxetine—Dyspnoea—Sorafenib—liver cancer	0.000998	0.00313	CcSEcCtD
Reboxetine—Dyspepsia—Sorafenib—liver cancer	0.000985	0.00309	CcSEcCtD
Reboxetine—Decreased appetite—Sorafenib—liver cancer	0.000973	0.00306	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Sorafenib—liver cancer	0.000967	0.00303	CcSEcCtD
Reboxetine—Constipation—Sorafenib—liver cancer	0.000957	0.00301	CcSEcCtD
Reboxetine—Mental disability—Doxorubicin—liver cancer	0.000931	0.00292	CcSEcCtD
Reboxetine—Gastrointestinal pain—Sorafenib—liver cancer	0.000915	0.00287	CcSEcCtD
Reboxetine—Urticaria—Sorafenib—liver cancer	0.000889	0.00279	CcSEcCtD
Reboxetine—Abdominal pain—Sorafenib—liver cancer	0.000885	0.00278	CcSEcCtD
Reboxetine—Body temperature increased—Sorafenib—liver cancer	0.000885	0.00278	CcSEcCtD
Reboxetine—Hyponatraemia—Epirubicin—liver cancer	0.000845	0.00265	CcSEcCtD
Reboxetine—Diplopia—Epirubicin—liver cancer	0.000842	0.00264	CcSEcCtD
Reboxetine—Hypersensitivity—Sorafenib—liver cancer	0.000825	0.00259	CcSEcCtD
Reboxetine—Face oedema—Epirubicin—liver cancer	0.000813	0.00255	CcSEcCtD
Reboxetine—Asthenia—Sorafenib—liver cancer	0.000803	0.00252	CcSEcCtD
Reboxetine—Blood creatinine increased—Epirubicin—liver cancer	0.000789	0.00248	CcSEcCtD
Reboxetine—Dehydration—Epirubicin—liver cancer	0.000783	0.00246	CcSEcCtD
Reboxetine—Hyponatraemia—Doxorubicin—liver cancer	0.000782	0.00246	CcSEcCtD
Reboxetine—Diplopia—Doxorubicin—liver cancer	0.000779	0.00245	CcSEcCtD
Reboxetine—Liver function test abnormal—Epirubicin—liver cancer	0.000777	0.00244	CcSEcCtD
Reboxetine—Orthostatic hypotension—Epirubicin—liver cancer	0.000769	0.00241	CcSEcCtD
Reboxetine—Diarrhoea—Sorafenib—liver cancer	0.000766	0.00241	CcSEcCtD
Reboxetine—Breast disorder—Epirubicin—liver cancer	0.000761	0.00239	CcSEcCtD
Reboxetine—Face oedema—Doxorubicin—liver cancer	0.000752	0.00236	CcSEcCtD
Reboxetine—Muscular weakness—Epirubicin—liver cancer	0.000742	0.00233	CcSEcCtD
Reboxetine—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000742	0.00233	CcSEcCtD
Reboxetine—Dizziness—Sorafenib—liver cancer	0.00074	0.00232	CcSEcCtD
Reboxetine—Blood creatinine increased—Doxorubicin—liver cancer	0.00073	0.00229	CcSEcCtD
Reboxetine—Influenza—Epirubicin—liver cancer	0.000728	0.00228	CcSEcCtD
Reboxetine—Dehydration—Doxorubicin—liver cancer	0.000724	0.00227	CcSEcCtD
Reboxetine—Liver function test abnormal—Doxorubicin—liver cancer	0.000719	0.00226	CcSEcCtD
Reboxetine—Vomiting—Sorafenib—liver cancer	0.000712	0.00224	CcSEcCtD
Reboxetine—Orthostatic hypotension—Doxorubicin—liver cancer	0.000711	0.00223	CcSEcCtD
Reboxetine—Rash—Sorafenib—liver cancer	0.000706	0.00222	CcSEcCtD
Reboxetine—Dermatitis—Sorafenib—liver cancer	0.000705	0.00221	CcSEcCtD
Reboxetine—Breast disorder—Doxorubicin—liver cancer	0.000704	0.00221	CcSEcCtD
Reboxetine—Headache—Sorafenib—liver cancer	0.000701	0.0022	CcSEcCtD
Reboxetine—Bronchitis—Epirubicin—liver cancer	0.0007	0.0022	CcSEcCtD
Reboxetine—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000687	0.00216	CcSEcCtD
Reboxetine—Muscular weakness—Doxorubicin—liver cancer	0.000687	0.00216	CcSEcCtD
Reboxetine—Dysuria—Epirubicin—liver cancer	0.00068	0.00214	CcSEcCtD
Reboxetine—Influenza—Doxorubicin—liver cancer	0.000673	0.00211	CcSEcCtD
Reboxetine—Pollakiuria—Epirubicin—liver cancer	0.000672	0.00211	CcSEcCtD
Reboxetine—Nausea—Sorafenib—liver cancer	0.000665	0.00209	CcSEcCtD
Reboxetine—Weight decreased—Epirubicin—liver cancer	0.000658	0.00207	CcSEcCtD
Reboxetine—Hyperglycaemia—Epirubicin—liver cancer	0.000656	0.00206	CcSEcCtD
Reboxetine—Infestation NOS—Epirubicin—liver cancer	0.000649	0.00204	CcSEcCtD
Reboxetine—Infestation—Epirubicin—liver cancer	0.000649	0.00204	CcSEcCtD
Reboxetine—Bronchitis—Doxorubicin—liver cancer	0.000647	0.00203	CcSEcCtD
Reboxetine—Conjunctivitis—Epirubicin—liver cancer	0.000631	0.00198	CcSEcCtD
Reboxetine—Urinary tract infection—Epirubicin—liver cancer	0.000631	0.00198	CcSEcCtD
Reboxetine—Dysuria—Doxorubicin—liver cancer	0.00063	0.00198	CcSEcCtD
Reboxetine—Sweating—Epirubicin—liver cancer	0.000622	0.00195	CcSEcCtD
Reboxetine—Pollakiuria—Doxorubicin—liver cancer	0.000622	0.00195	CcSEcCtD
Reboxetine—Epistaxis—Epirubicin—liver cancer	0.000612	0.00192	CcSEcCtD
Reboxetine—Weight decreased—Doxorubicin—liver cancer	0.000609	0.00191	CcSEcCtD
Reboxetine—Sinusitis—Epirubicin—liver cancer	0.000609	0.00191	CcSEcCtD
Reboxetine—Hyperglycaemia—Doxorubicin—liver cancer	0.000607	0.00191	CcSEcCtD
Reboxetine—Infestation NOS—Doxorubicin—liver cancer	0.0006	0.00188	CcSEcCtD
Reboxetine—Infestation—Doxorubicin—liver cancer	0.0006	0.00188	CcSEcCtD
Reboxetine—Bradycardia—Epirubicin—liver cancer	0.000593	0.00186	CcSEcCtD
Reboxetine—Rhinitis—Epirubicin—liver cancer	0.000584	0.00183	CcSEcCtD
Reboxetine—Conjunctivitis—Doxorubicin—liver cancer	0.000583	0.00183	CcSEcCtD
Reboxetine—Urinary tract infection—Doxorubicin—liver cancer	0.000583	0.00183	CcSEcCtD
Reboxetine—Pharyngitis—Epirubicin—liver cancer	0.000578	0.00181	CcSEcCtD
Reboxetine—Sweating—Doxorubicin—liver cancer	0.000575	0.00181	CcSEcCtD
Reboxetine—Urinary tract disorder—Epirubicin—liver cancer	0.000575	0.00181	CcSEcCtD
Reboxetine—Connective tissue disorder—Epirubicin—liver cancer	0.000572	0.0018	CcSEcCtD
Reboxetine—Urethral disorder—Epirubicin—liver cancer	0.000571	0.00179	CcSEcCtD
Reboxetine—Epistaxis—Doxorubicin—liver cancer	0.000566	0.00178	CcSEcCtD
Reboxetine—Sinusitis—Doxorubicin—liver cancer	0.000563	0.00177	CcSEcCtD
Reboxetine—Visual impairment—Epirubicin—liver cancer	0.000561	0.00176	CcSEcCtD
Reboxetine—Bradycardia—Doxorubicin—liver cancer	0.000549	0.00172	CcSEcCtD
Reboxetine—Eye disorder—Epirubicin—liver cancer	0.000544	0.00171	CcSEcCtD
Reboxetine—Tinnitus—Epirubicin—liver cancer	0.000543	0.0017	CcSEcCtD
Reboxetine—Cardiac disorder—Epirubicin—liver cancer	0.00054	0.0017	CcSEcCtD
Reboxetine—Rhinitis—Doxorubicin—liver cancer	0.00054	0.0017	CcSEcCtD
Reboxetine—Pharyngitis—Doxorubicin—liver cancer	0.000535	0.00168	CcSEcCtD
Reboxetine—Urinary tract disorder—Doxorubicin—liver cancer	0.000532	0.00167	CcSEcCtD
Reboxetine—Connective tissue disorder—Doxorubicin—liver cancer	0.00053	0.00166	CcSEcCtD
Reboxetine—Angiopathy—Epirubicin—liver cancer	0.000528	0.00166	CcSEcCtD
Reboxetine—Urethral disorder—Doxorubicin—liver cancer	0.000528	0.00166	CcSEcCtD
Reboxetine—Immune system disorder—Epirubicin—liver cancer	0.000526	0.00165	CcSEcCtD
Reboxetine—Mediastinal disorder—Epirubicin—liver cancer	0.000525	0.00165	CcSEcCtD
Reboxetine—Chills—Epirubicin—liver cancer	0.000523	0.00164	CcSEcCtD
Reboxetine—Visual impairment—Doxorubicin—liver cancer	0.000519	0.00163	CcSEcCtD
Reboxetine—Mental disorder—Epirubicin—liver cancer	0.00051	0.0016	CcSEcCtD
Reboxetine—Malnutrition—Epirubicin—liver cancer	0.000507	0.00159	CcSEcCtD
Reboxetine—Eye disorder—Doxorubicin—liver cancer	0.000504	0.00158	CcSEcCtD
Reboxetine—Tinnitus—Doxorubicin—liver cancer	0.000502	0.00158	CcSEcCtD
Reboxetine—Cardiac disorder—Doxorubicin—liver cancer	0.0005	0.00157	CcSEcCtD
Reboxetine—Tension—Epirubicin—liver cancer	0.000497	0.00156	CcSEcCtD
Reboxetine—Dysgeusia—Epirubicin—liver cancer	0.000496	0.00156	CcSEcCtD
Reboxetine—Nervousness—Epirubicin—liver cancer	0.000492	0.00155	CcSEcCtD
Reboxetine—Angiopathy—Doxorubicin—liver cancer	0.000489	0.00154	CcSEcCtD
Reboxetine—Immune system disorder—Doxorubicin—liver cancer	0.000487	0.00153	CcSEcCtD
Reboxetine—Mediastinal disorder—Doxorubicin—liver cancer	0.000486	0.00152	CcSEcCtD
Reboxetine—Chills—Doxorubicin—liver cancer	0.000483	0.00152	CcSEcCtD
Reboxetine—Mental disorder—Doxorubicin—liver cancer	0.000472	0.00148	CcSEcCtD
Reboxetine—Ill-defined disorder—Epirubicin—liver cancer	0.00047	0.00148	CcSEcCtD
Reboxetine—Malnutrition—Doxorubicin—liver cancer	0.000469	0.00147	CcSEcCtD
Reboxetine—Anaemia—Epirubicin—liver cancer	0.000469	0.00147	CcSEcCtD
Reboxetine—Agitation—Epirubicin—liver cancer	0.000466	0.00146	CcSEcCtD
Reboxetine—Tension—Doxorubicin—liver cancer	0.00046	0.00145	CcSEcCtD
Reboxetine—Dysgeusia—Doxorubicin—liver cancer	0.000459	0.00144	CcSEcCtD
Reboxetine—Malaise—Epirubicin—liver cancer	0.000457	0.00144	CcSEcCtD
Reboxetine—Nervousness—Doxorubicin—liver cancer	0.000456	0.00143	CcSEcCtD
Reboxetine—Vertigo—Epirubicin—liver cancer	0.000455	0.00143	CcSEcCtD
Reboxetine—Syncope—Epirubicin—liver cancer	0.000455	0.00143	CcSEcCtD
Reboxetine—Leukopenia—Epirubicin—liver cancer	0.000454	0.00142	CcSEcCtD
Reboxetine—Palpitations—Epirubicin—liver cancer	0.000448	0.00141	CcSEcCtD
Reboxetine—Loss of consciousness—Epirubicin—liver cancer	0.000446	0.0014	CcSEcCtD
Reboxetine—Hypertension—Epirubicin—liver cancer	0.000438	0.00137	CcSEcCtD
Reboxetine—Ill-defined disorder—Doxorubicin—liver cancer	0.000435	0.00137	CcSEcCtD
Reboxetine—Anaemia—Doxorubicin—liver cancer	0.000434	0.00136	CcSEcCtD
Reboxetine—Chest pain—Epirubicin—liver cancer	0.000432	0.00136	CcSEcCtD
Reboxetine—Agitation—Doxorubicin—liver cancer	0.000431	0.00135	CcSEcCtD
Reboxetine—Anxiety—Epirubicin—liver cancer	0.00043	0.00135	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000429	0.00135	CcSEcCtD
Reboxetine—Discomfort—Epirubicin—liver cancer	0.000426	0.00134	CcSEcCtD
Reboxetine—Malaise—Doxorubicin—liver cancer	0.000423	0.00133	CcSEcCtD
Reboxetine—Dry mouth—Epirubicin—liver cancer	0.000422	0.00133	CcSEcCtD
Reboxetine—Vertigo—Doxorubicin—liver cancer	0.000421	0.00132	CcSEcCtD
Reboxetine—Syncope—Doxorubicin—liver cancer	0.000421	0.00132	CcSEcCtD
Reboxetine—Leukopenia—Doxorubicin—liver cancer	0.00042	0.00132	CcSEcCtD
Reboxetine—Confusional state—Epirubicin—liver cancer	0.000417	0.00131	CcSEcCtD
Reboxetine—Palpitations—Doxorubicin—liver cancer	0.000415	0.0013	CcSEcCtD
Reboxetine—Loss of consciousness—Doxorubicin—liver cancer	0.000412	0.00129	CcSEcCtD
Reboxetine—Infection—Epirubicin—liver cancer	0.000411	0.00129	CcSEcCtD
Reboxetine—Shock—Epirubicin—liver cancer	0.000407	0.00128	CcSEcCtD
Reboxetine—Nervous system disorder—Epirubicin—liver cancer	0.000406	0.00127	CcSEcCtD
Reboxetine—Hypertension—Doxorubicin—liver cancer	0.000405	0.00127	CcSEcCtD
Reboxetine—Tachycardia—Epirubicin—liver cancer	0.000404	0.00127	CcSEcCtD
Reboxetine—Skin disorder—Epirubicin—liver cancer	0.000402	0.00126	CcSEcCtD
Reboxetine—Hyperhidrosis—Epirubicin—liver cancer	0.0004	0.00126	CcSEcCtD
Reboxetine—Chest pain—Doxorubicin—liver cancer	0.000399	0.00125	CcSEcCtD
Reboxetine—Anxiety—Doxorubicin—liver cancer	0.000398	0.00125	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000397	0.00125	CcSEcCtD
Reboxetine—Discomfort—Doxorubicin—liver cancer	0.000395	0.00124	CcSEcCtD
Reboxetine—Anorexia—Epirubicin—liver cancer	0.000394	0.00124	CcSEcCtD
Reboxetine—Dry mouth—Doxorubicin—liver cancer	0.000391	0.00123	CcSEcCtD
Reboxetine—Hypotension—Epirubicin—liver cancer	0.000387	0.00121	CcSEcCtD
Reboxetine—Confusional state—Doxorubicin—liver cancer	0.000386	0.00121	CcSEcCtD
Reboxetine—Infection—Doxorubicin—liver cancer	0.00038	0.00119	CcSEcCtD
Reboxetine—Shock—Doxorubicin—liver cancer	0.000377	0.00118	CcSEcCtD
Reboxetine—Nervous system disorder—Doxorubicin—liver cancer	0.000375	0.00118	CcSEcCtD
Reboxetine—Insomnia—Epirubicin—liver cancer	0.000374	0.00118	CcSEcCtD
Reboxetine—Tachycardia—Doxorubicin—liver cancer	0.000374	0.00117	CcSEcCtD
Reboxetine—Skin disorder—Doxorubicin—liver cancer	0.000372	0.00117	CcSEcCtD
Reboxetine—Paraesthesia—Epirubicin—liver cancer	0.000372	0.00117	CcSEcCtD
Reboxetine—Hyperhidrosis—Doxorubicin—liver cancer	0.00037	0.00116	CcSEcCtD
Reboxetine—Dyspnoea—Epirubicin—liver cancer	0.000369	0.00116	CcSEcCtD
Reboxetine—Somnolence—Epirubicin—liver cancer	0.000368	0.00115	CcSEcCtD
Reboxetine—Anorexia—Doxorubicin—liver cancer	0.000365	0.00115	CcSEcCtD
Reboxetine—Dyspepsia—Epirubicin—liver cancer	0.000364	0.00114	CcSEcCtD
Reboxetine—Decreased appetite—Epirubicin—liver cancer	0.00036	0.00113	CcSEcCtD
Reboxetine—Hypotension—Doxorubicin—liver cancer	0.000358	0.00112	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000357	0.00112	CcSEcCtD
Reboxetine—Constipation—Epirubicin—liver cancer	0.000354	0.00111	CcSEcCtD
Reboxetine—Insomnia—Doxorubicin—liver cancer	0.000346	0.00109	CcSEcCtD
Reboxetine—Paraesthesia—Doxorubicin—liver cancer	0.000344	0.00108	CcSEcCtD
Reboxetine—Dyspnoea—Doxorubicin—liver cancer	0.000341	0.00107	CcSEcCtD
Reboxetine—Feeling abnormal—Epirubicin—liver cancer	0.000341	0.00107	CcSEcCtD
Reboxetine—Somnolence—Doxorubicin—liver cancer	0.00034	0.00107	CcSEcCtD
Reboxetine—Gastrointestinal pain—Epirubicin—liver cancer	0.000338	0.00106	CcSEcCtD
Reboxetine—Dyspepsia—Doxorubicin—liver cancer	0.000337	0.00106	CcSEcCtD
Reboxetine—Decreased appetite—Doxorubicin—liver cancer	0.000333	0.00104	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000331	0.00104	CcSEcCtD
Reboxetine—Urticaria—Epirubicin—liver cancer	0.000329	0.00103	CcSEcCtD
Reboxetine—Constipation—Doxorubicin—liver cancer	0.000327	0.00103	CcSEcCtD
Reboxetine—Body temperature increased—Epirubicin—liver cancer	0.000327	0.00103	CcSEcCtD
Reboxetine—Abdominal pain—Epirubicin—liver cancer	0.000327	0.00103	CcSEcCtD
Reboxetine—Feeling abnormal—Doxorubicin—liver cancer	0.000315	0.000991	CcSEcCtD
Reboxetine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000313	0.000983	CcSEcCtD
Reboxetine—Hypersensitivity—Epirubicin—liver cancer	0.000305	0.000957	CcSEcCtD
Reboxetine—Urticaria—Doxorubicin—liver cancer	0.000304	0.000955	CcSEcCtD
Reboxetine—Abdominal pain—Doxorubicin—liver cancer	0.000303	0.00095	CcSEcCtD
Reboxetine—Body temperature increased—Doxorubicin—liver cancer	0.000303	0.00095	CcSEcCtD
Reboxetine—Asthenia—Epirubicin—liver cancer	0.000297	0.000932	CcSEcCtD
Reboxetine—Diarrhoea—Epirubicin—liver cancer	0.000283	0.000889	CcSEcCtD
Reboxetine—Hypersensitivity—Doxorubicin—liver cancer	0.000282	0.000886	CcSEcCtD
Reboxetine—Asthenia—Doxorubicin—liver cancer	0.000275	0.000862	CcSEcCtD
Reboxetine—Dizziness—Epirubicin—liver cancer	0.000274	0.000859	CcSEcCtD
Reboxetine—Vomiting—Epirubicin—liver cancer	0.000263	0.000826	CcSEcCtD
Reboxetine—Diarrhoea—Doxorubicin—liver cancer	0.000262	0.000822	CcSEcCtD
Reboxetine—Rash—Epirubicin—liver cancer	0.000261	0.000819	CcSEcCtD
Reboxetine—Dermatitis—Epirubicin—liver cancer	0.000261	0.000818	CcSEcCtD
Reboxetine—Headache—Epirubicin—liver cancer	0.000259	0.000814	CcSEcCtD
Reboxetine—Dizziness—Doxorubicin—liver cancer	0.000253	0.000795	CcSEcCtD
Reboxetine—Nausea—Epirubicin—liver cancer	0.000246	0.000772	CcSEcCtD
Reboxetine—Vomiting—Doxorubicin—liver cancer	0.000243	0.000764	CcSEcCtD
Reboxetine—Rash—Doxorubicin—liver cancer	0.000241	0.000758	CcSEcCtD
Reboxetine—Dermatitis—Doxorubicin—liver cancer	0.000241	0.000757	CcSEcCtD
Reboxetine—Headache—Doxorubicin—liver cancer	0.00024	0.000753	CcSEcCtD
Reboxetine—Nausea—Doxorubicin—liver cancer	0.000227	0.000714	CcSEcCtD
Reboxetine—CYP2D6—Biological oxidations—GGT1—liver cancer	0.000102	0.00145	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—MAPK8—liver cancer	0.000101	0.00143	CbGpPWpGaD
Reboxetine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—liver cancer	0.0001	0.00142	CbGpPWpGaD
Reboxetine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	9.87e-05	0.0014	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—JUN—liver cancer	9.82e-05	0.00139	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—liver cancer	9.75e-05	0.00138	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—TGFB1—liver cancer	9.47e-05	0.00134	CbGpPWpGaD
Reboxetine—SLC6A2—SLC-mediated transmembrane transport—ALB—liver cancer	9.44e-05	0.00134	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	9.39e-05	0.00133	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—GSTP1—liver cancer	9.2e-05	0.00131	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—CYCS—liver cancer	9.19e-05	0.0013	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—SLC11A2—liver cancer	9.18e-05	0.0013	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—GSTP1—liver cancer	9.08e-05	0.00129	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—HPGDS—liver cancer	8.95e-05	0.00127	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—TRIO—liver cancer	8.87e-05	0.00126	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	8.78e-05	0.00125	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—SLC40A1—liver cancer	8.75e-05	0.00124	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—CASP3—liver cancer	8.75e-05	0.00124	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—IL2—liver cancer	8.74e-05	0.00124	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—liver cancer	8.58e-05	0.00122	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—CCR4—liver cancer	8.5e-05	0.00121	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—GSTM1—liver cancer	8.46e-05	0.0012	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—ANXA2—liver cancer	8.39e-05	0.00119	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—ATP7B—liver cancer	8.39e-05	0.00119	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—GSTM1—liver cancer	8.34e-05	0.00118	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—TRIO—liver cancer	8.05e-05	0.00114	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—CYP1A1—liver cancer	8.02e-05	0.00114	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—liver cancer	8.01e-05	0.00114	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—HMOX1—liver cancer	7.99e-05	0.00113	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—NR1H4—liver cancer	7.94e-05	0.00113	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—CYP1A1—liver cancer	7.91e-05	0.00112	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	7.9e-05	0.00112	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—liver cancer	7.87e-05	0.00112	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—CCR4—liver cancer	7.72e-05	0.0011	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	7.53e-05	0.00107	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—VEGFA—liver cancer	7.43e-05	0.00105	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—CYP2E1—liver cancer	7.3e-05	0.00104	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	7.2e-05	0.00102	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—TP53—liver cancer	7.02e-05	0.000996	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—TGFB1—liver cancer	6.82e-05	0.000967	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GGT1—liver cancer	6.7e-05	0.000951	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	6.61e-05	0.000938	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	6.48e-05	0.00092	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—PPARA—liver cancer	6.45e-05	0.000916	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—IL6—liver cancer	6.43e-05	0.000912	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—SHC3—liver cancer	6.42e-05	0.000911	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—TNF—liver cancer	6.36e-05	0.000903	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—UGDH—liver cancer	6.36e-05	0.000903	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	6.13e-05	0.00087	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GSTP1—liver cancer	6.02e-05	0.000854	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—F2—liver cancer	6.01e-05	0.000853	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—UGDH—liver cancer	6e-05	0.000851	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—EPT1—liver cancer	5.98e-05	0.000849	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	5.93e-05	0.000842	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—TAT—liver cancer	5.67e-05	0.000805	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—EPT1—liver cancer	5.64e-05	0.0008	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GSTM1—liver cancer	5.53e-05	0.000785	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	5.47e-05	0.000777	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	5.45e-05	0.000774	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—TAT—liver cancer	5.34e-05	0.000759	CbGpPWpGaD
Reboxetine—HTR2C—G alpha (q) signalling events—PIK3CA—liver cancer	5.33e-05	0.000756	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—CYP1A1—liver cancer	5.24e-05	0.000744	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	5.19e-05	0.000736	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	5.17e-05	0.000734	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—FST—liver cancer	4.99e-05	0.000708	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—PRKCE—liver cancer	4.89e-05	0.000695	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	4.81e-05	0.000683	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—ALB—liver cancer	4.8e-05	0.000681	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	4.77e-05	0.000676	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TRIO—liver cancer	4.76e-05	0.000675	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CCR4—liver cancer	4.56e-05	0.000647	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—PRKCE—liver cancer	4.44e-05	0.000631	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	4.41e-05	0.000626	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	4.41e-05	0.000625	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—RAF1—liver cancer	4.34e-05	0.000615	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—CSF2—liver cancer	4.33e-05	0.000615	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	4.32e-05	0.000613	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	4.22e-05	0.000599	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	4.2e-05	0.000597	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	4.2e-05	0.000595	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	4.16e-05	0.000591	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	4.07e-05	0.000577	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	4.05e-05	0.000574	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	3.97e-05	0.000563	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—CSF2—liver cancer	3.93e-05	0.000558	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—UGDH—liver cancer	3.92e-05	0.000556	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GLUL—liver cancer	3.86e-05	0.000547	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CPT1B—liver cancer	3.86e-05	0.000547	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NR1H4—liver cancer	3.72e-05	0.000528	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—EPT1—liver cancer	3.69e-05	0.000523	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	3.66e-05	0.00052	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTA3—liver cancer	3.65e-05	0.000519	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CPT1B—liver cancer	3.63e-05	0.000516	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GLUL—liver cancer	3.63e-05	0.000516	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ADAM17—liver cancer	3.6e-05	0.000512	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	3.52e-05	0.000499	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NR1H4—liver cancer	3.5e-05	0.000497	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—TAT—liver cancer	3.49e-05	0.000496	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTA3—liver cancer	3.44e-05	0.000489	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—F2—liver cancer	3.4e-05	0.000482	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PSMD10—liver cancer	3.39e-05	0.000481	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PSMA4—liver cancer	3.39e-05	0.000481	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	3.37e-05	0.000479	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	3.36e-05	0.000477	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTA4—liver cancer	3.34e-05	0.000474	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTA2—liver cancer	3.26e-05	0.000462	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—PIK3CG—liver cancer	3.25e-05	0.000461	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTA4—liver cancer	3.15e-05	0.000447	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTA1—liver cancer	3.14e-05	0.000446	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	3.14e-05	0.000446	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	3.12e-05	0.000442	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NAT2—liver cancer	3.11e-05	0.000441	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—F2—liver cancer	3.09e-05	0.000438	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTA2—liver cancer	3.07e-05	0.000436	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ALDOB—liver cancer	2.98e-05	0.000423	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTA1—liver cancer	2.96e-05	0.00042	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—PIK3CG—liver cancer	2.95e-05	0.000419	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NAT2—liver cancer	2.93e-05	0.000416	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	2.86e-05	0.000406	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—PIK3CD—liver cancer	2.86e-05	0.000406	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CRABP1—liver cancer	2.84e-05	0.000403	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	2.84e-05	0.000403	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ALDOB—liver cancer	2.81e-05	0.000398	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	2.77e-05	0.000393	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CRABP1—liver cancer	2.68e-05	0.00038	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PRKCE—liver cancer	2.63e-05	0.000373	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—PIK3CD—liver cancer	2.6e-05	0.000368	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—PIK3CB—liver cancer	2.49e-05	0.000354	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IGF2—liver cancer	2.49e-05	0.000353	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—HPGDS—liver cancer	2.48e-05	0.000353	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GLUL—liver cancer	2.38e-05	0.000337	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CPT1B—liver cancer	2.38e-05	0.000337	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—HPGDS—liver cancer	2.34e-05	0.000332	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	2.34e-05	0.000332	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CSF2—liver cancer	2.32e-05	0.00033	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—RAF1—liver cancer	2.32e-05	0.000329	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NR1H4—liver cancer	2.29e-05	0.000325	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—H2AFX—liver cancer	2.29e-05	0.000325	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—IL2—liver cancer	2.29e-05	0.000325	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—PIK3CB—liver cancer	2.26e-05	0.000321	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTA3—liver cancer	2.25e-05	0.00032	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PSMA4—liver cancer	2.21e-05	0.000314	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PSMD10—liver cancer	2.21e-05	0.000314	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GOT2—liver cancer	2.15e-05	0.000306	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	2.11e-05	0.0003	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PSMD10—liver cancer	2.09e-05	0.000296	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PSMA4—liver cancer	2.09e-05	0.000296	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—IL2—liver cancer	2.08e-05	0.000295	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TERT—liver cancer	2.07e-05	0.000294	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTA4—liver cancer	2.06e-05	0.000292	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GOT2—liver cancer	2.03e-05	0.000288	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP2E1—liver cancer	2.03e-05	0.000287	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTA2—liver cancer	2.01e-05	0.000285	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTA1—liver cancer	1.94e-05	0.000275	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NAT2—liver cancer	1.91e-05	0.000272	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.91e-05	0.000271	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP2E1—liver cancer	1.91e-05	0.000271	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYCS—liver cancer	1.89e-05	0.000269	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—KDR—liver cancer	1.89e-05	0.000269	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MAPK14—liver cancer	1.88e-05	0.000267	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GGT1—liver cancer	1.86e-05	0.000264	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GOT1—liver cancer	1.86e-05	0.000264	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ESR1—liver cancer	1.85e-05	0.000262	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ALDOB—liver cancer	1.84e-05	0.000261	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—F2—liver cancer	1.82e-05	0.000259	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYCS—liver cancer	1.79e-05	0.000253	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GOT1—liver cancer	1.75e-05	0.000249	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GGT1—liver cancer	1.75e-05	0.000249	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CRABP1—liver cancer	1.75e-05	0.000249	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—APC—liver cancer	1.74e-05	0.000248	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PIK3CG—liver cancer	1.74e-05	0.000248	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTP1—liver cancer	1.67e-05	0.000237	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—HMOX1—liver cancer	1.65e-05	0.000234	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—BRAF—liver cancer	1.64e-05	0.000233	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTP1—liver cancer	1.57e-05	0.000223	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—HMOX1—liver cancer	1.55e-05	0.00022	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTM1—liver cancer	1.53e-05	0.000218	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PIK3CD—liver cancer	1.53e-05	0.000218	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—HPGDS—liver cancer	1.53e-05	0.000217	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—PIK3CA—liver cancer	1.52e-05	0.000216	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—SERPINE1—liver cancer	1.52e-05	0.000215	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—KRAS—liver cancer	1.5e-05	0.000213	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP1A1—liver cancer	1.45e-05	0.000206	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTM1—liver cancer	1.45e-05	0.000205	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—PIK3CA—liver cancer	1.38e-05	0.000196	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP1A1—liver cancer	1.37e-05	0.000195	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—RAF1—liver cancer	1.37e-05	0.000194	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PSMD10—liver cancer	1.36e-05	0.000194	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PSMA4—liver cancer	1.36e-05	0.000194	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—MTHFR—liver cancer	1.36e-05	0.000193	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MTOR—liver cancer	1.34e-05	0.00019	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PIK3CB—liver cancer	1.34e-05	0.00019	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PPARA—liver cancer	1.33e-05	0.000189	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GOT2—liver cancer	1.33e-05	0.000188	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—MTHFR—liver cancer	1.28e-05	0.000181	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—HRAS—liver cancer	1.28e-05	0.000181	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CDKN1B—liver cancer	1.25e-05	0.000178	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PPARA—liver cancer	1.25e-05	0.000178	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP2E1—liver cancer	1.25e-05	0.000177	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—AKT1—liver cancer	1.24e-05	0.000176	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CASP3—liver cancer	1.23e-05	0.000174	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IL2—liver cancer	1.23e-05	0.000174	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—IL6—liver cancer	1.22e-05	0.000173	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CCND1—liver cancer	1.2e-05	0.00017	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—JUN—liver cancer	1.19e-05	0.000169	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CTNNB1—liver cancer	1.18e-05	0.000168	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYCS—liver cancer	1.17e-05	0.000166	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MMP9—liver cancer	1.16e-05	0.000165	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CDKN1A—liver cancer	1.16e-05	0.000164	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GGT1—liver cancer	1.15e-05	0.000163	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GOT1—liver cancer	1.15e-05	0.000163	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PIK3CG—liver cancer	1.14e-05	0.000162	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MAPK8—liver cancer	1.13e-05	0.00016	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—AKT1—liver cancer	1.13e-05	0.00016	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PPARG—liver cancer	1.1e-05	0.000156	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PIK3CG—liver cancer	1.07e-05	0.000152	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—VEGFA—liver cancer	1.04e-05	0.000148	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PPARG—liver cancer	1.04e-05	0.000147	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—STAT3—liver cancer	1.03e-05	0.000147	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTP1—liver cancer	1.03e-05	0.000146	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—HMOX1—liver cancer	1.01e-05	0.000144	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PIK3CD—liver cancer	1e-05	0.000142	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ALB—liver cancer	9.89e-06	0.00014	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MYC—liver cancer	9.6e-06	0.000136	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TGFB1—liver cancer	9.57e-06	0.000136	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTM1—liver cancer	9.46e-06	0.000134	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PIK3CD—liver cancer	9.44e-06	0.000134	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ALB—liver cancer	9.32e-06	0.000132	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP1A1—liver cancer	8.96e-06	0.000127	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—KRAS—liver cancer	8.87e-06	0.000126	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PIK3CB—liver cancer	8.73e-06	0.000124	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—MTHFR—liver cancer	8.36e-06	0.000119	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PIK3CB—liver cancer	8.23e-06	0.000117	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PPARA—liver cancer	8.2e-06	0.000116	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PIK3CA—liver cancer	8.15e-06	0.000116	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TP53—liver cancer	7.88e-06	0.000112	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—HRAS—liver cancer	7.54e-06	0.000107	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IL6—liver cancer	7.21e-06	0.000102	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PIK3CG—liver cancer	7.02e-06	9.97e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PPARG—liver cancer	6.78e-06	9.62e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—AKT1—liver cancer	6.66e-06	9.45e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PIK3CD—liver cancer	6.17e-06	8.76e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ALB—liver cancer	6.09e-06	8.65e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PIK3CB—liver cancer	5.38e-06	7.64e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PIK3CA—liver cancer	5.32e-06	7.56e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PIK3CA—liver cancer	5.02e-06	7.12e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—AKT1—liver cancer	4.35e-06	6.17e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—AKT1—liver cancer	4.1e-06	5.82e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PIK3CA—liver cancer	3.28e-06	4.65e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—AKT1—liver cancer	2.68e-06	3.8e-05	CbGpPWpGaD
